The pyruvate dehydrogenase E1 subunit beta (PDHB) gene encodes a critical component of the mitochondrial pyruvate dehydrogenase complex (PDC), which catalyzes the conversion of pyruvate to acetyl-CoA, linking glycolysis to the citric acid cycle. As a metabolic hub, PDC activity is tightly regulated, and PDHB dysfunction is associated with rare genetic disorders like pyruvate dehydrogenase deficiency, characterized by lactic acidosis and neurological impairments. PDHB antibodies are essential tools for studying the expression, localization, and functional roles of this subunit in health and disease. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess PDHB protein levels in tissues or cell lines, particularly in research on metabolic disorders, cancer (where altered PDC activity influences the Warburg effect), and neurodegenerative conditions. Commercially available PDHB antibodies are typically developed in rabbit or mouse hosts, targeting specific epitopes to ensure specificity. Recent studies also utilize these antibodies to explore post-translational modifications (e.g., phosphorylation) impacting PDC activity. Validated PDHB reagents help dissect metabolic adaptations in diseases and potential therapeutic targets, underscoring their importance in mitochondrial and metabolic research.